Denali Therapeutics Inc. Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax
Denali Therapeutics Inc. (DNLI) had Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax of $1.29 million as of 2018-03-31, per its 10-Q filed 2018-05-11.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax · last filed 2018-05-11
- 2018-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $1.29M.
- 2017-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax $368.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax |
|---|---|
| 2018-03-31 | $1.29M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $368.00K 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |